Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes

Jing Quan Zheng, Kun Wang, Dee Pei, Yen Lin Chen, Yen Lin Chang, Chun Hsien Hsu, Tsan Ming Huang, Mei Yu Lin, Pao Ying Lin, Jiunn Diann Lin

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function. Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period. Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found. Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.

Original languageEnglish
Pages (from-to)372-376
Number of pages5
JournalIndian Journal of Pharmacology
Volume44
Issue number3
DOIs
Publication statusPublished - Jun 2012

Fingerprint

rosiglitazone
Type 2 Diabetes Mellitus
Liver
Enzymes
Therapeutics
Aspartate Aminotransferases
Alanine Transaminase
Hemoglobins

Keywords

  • liver function
  • Rosiglitazone
  • type 2 diabetes

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes. / Zheng, Jing Quan; Wang, Kun; Pei, Dee; Chen, Yen Lin; Chang, Yen Lin; Hsu, Chun Hsien; Huang, Tsan Ming; Lin, Mei Yu; Lin, Pao Ying; Lin, Jiunn Diann.

In: Indian Journal of Pharmacology, Vol. 44, No. 3, 06.2012, p. 372-376.

Research output: Contribution to journalArticle

Zheng, Jing Quan ; Wang, Kun ; Pei, Dee ; Chen, Yen Lin ; Chang, Yen Lin ; Hsu, Chun Hsien ; Huang, Tsan Ming ; Lin, Mei Yu ; Lin, Pao Ying ; Lin, Jiunn Diann. / Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes. In: Indian Journal of Pharmacology. 2012 ; Vol. 44, No. 3. pp. 372-376.
@article{d744dbefd24442e9840cb5dad03686b1,
title = "Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes",
abstract = "Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function. Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period. Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found. Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.",
keywords = "liver function, Rosiglitazone, type 2 diabetes",
author = "Zheng, {Jing Quan} and Kun Wang and Dee Pei and Chen, {Yen Lin} and Chang, {Yen Lin} and Hsu, {Chun Hsien} and Huang, {Tsan Ming} and Lin, {Mei Yu} and Lin, {Pao Ying} and Lin, {Jiunn Diann}",
year = "2012",
month = "6",
doi = "10.4103/0253-7613.96340",
language = "English",
volume = "44",
pages = "372--376",
journal = "Indian Journal of Pharmacology",
issn = "0253-7613",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "3",

}

TY - JOUR

T1 - Improvement of abnormal liver enzymes after rosiglitazone treatment in Chinese type 2 diabetes

AU - Zheng, Jing Quan

AU - Wang, Kun

AU - Pei, Dee

AU - Chen, Yen Lin

AU - Chang, Yen Lin

AU - Hsu, Chun Hsien

AU - Huang, Tsan Ming

AU - Lin, Mei Yu

AU - Lin, Pao Ying

AU - Lin, Jiunn Diann

PY - 2012/6

Y1 - 2012/6

N2 - Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function. Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period. Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found. Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.

AB - Objectives: Insulin resistance is one of the important underlying abnormalities of type 2 diabetes. The effect of thiazolidinedione on liver functions has been controversial in different studies. In this study, we evaluated the effect of rosiglitazone on liver enzymes in subjects with type 2 diabetes with and without abnormal liver function. Materials and Methods: Seventy-three patients with type 2 diabetes taking rosiglitazone 4 mg daily were enrolled in this 3-month study. Forty-two of them had normal liver function (NLF), and 31 had abnormal liver function (ABLF). Blood biochemistries were collected monthly during the treatment period. Results: At baseline, other than age and liver enzymes, there were no differences in body mass index, fasting plasma glucose, hemoglobin A1c (HbA1c), and lipid profiles between the NLF and ABLF groups. At the end of the treatment, HbA1c was lowered in both groups, but only significantly in the ABLF group (P = 0.027). More importantly, serum concentrations of both aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in the ABLF group decreased significantly (AST: 57.8 ± 26.5 to 47.5 ± 20.2 U/L, P = 0.006; ALT 66.6 ± 35.0 to 51.9 ± 23.5 UL, P = 0.004), while in the NLF group, a similar change was not found. Conclusion: After 3-month rosiglitazone treatment in subjects with type 2 diabetes with mildly elevated liver enzymes, significant improvement in AST and ALT were observed. Our study provides some hints that rosiglitazone might not be contraindicated in subjects with diabetes with abnormal liver function as previously thought, but further well-designed studies are necessary to clarify this issue.

KW - liver function

KW - Rosiglitazone

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=84861910667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861910667&partnerID=8YFLogxK

U2 - 10.4103/0253-7613.96340

DO - 10.4103/0253-7613.96340

M3 - Article

C2 - 22701249

AN - SCOPUS:84861910667

VL - 44

SP - 372

EP - 376

JO - Indian Journal of Pharmacology

JF - Indian Journal of Pharmacology

SN - 0253-7613

IS - 3

ER -